Selective Ubiquitin Specific Protease Inhibitors for Treatment of Multiple Myeloma and Other Cancers

Track Code: 2017-PEPE-67704

Categories:
- Chemistry and Chemical Analysis
- Pharmaceuticals

Keywords:
- Cancer
- Chemistry and Chemical Analysis
- Drug Development
- Inhibitors
- Pharmaceuticals
- Protease Inhibitors

Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma cells found in bone marrow are an important part of the immune system (American Cancer Society). In 2017, the American Cancer Society estimates approximately 30,280 new multiple myeloma cases diagnosed in the United States with approximately 12,590 deaths expected. Current methods of treatment include immunomodulatory drugs, stem cell transplants, and proteasome inhibitors. However, multiple myeloma remains incurable. Current treatment methods have issues with side effects and the potential for the development of resistance. Thus, there is an urgent need for the development of novel therapeutic agents.

Researchers at Purdue University have uncovered a new set of molecules that selectively inhibit ubiquitin specific protease 7 (USP7) without affecting similar enzymes. Inhibition of USP7 is important for the treatment of multiple myeloma, as well as for other diseases characterized by aberrant ubiquitin-mediated processes, such as many cancer, inflammation, and immunological disorders. The molecules identified by Purdue researchers have broad potential for the development of therapeutics to treat cancer and other diseases.

Advantages:
- Selective inhibition
- Targets key enzymes

Potential Applications:
- Pharmaceutical industry
- Drug development
- Treatment for cancer and other diseases
People:
- Pepe, Antonella (Project leader)
- Mesecar, Andrew D

Intellectual Property:

Application Date: September 13, 2019
Type: NATL-Patent
Country of Filing: United States
Patent Number: 10,980,781
Issue Date: April 20, 2021

Application Date: March 12, 2021
Type: DIV-Patent
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Application Date: March 29, 2018
Type: PCT-Patent
Country of Filing: WO
Patent Number: (None)
Issue Date: (None)

Application Date: March 29, 2017
Type: Provisional-Patent
Country of Filing: United States
Patent Number: (None)
Issue Date: (None)

Contact OTC:
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org